Source comparison
BPC-157 Scar Healing Mechanism: Research vs Clinical Comparison
Angiogenesis (VEGF upregulation) 340% increase in capillary density (rat models, 7 days post-injury) Improved wound perfusion measurable via laser Doppler NO pathway must be intact—blunted in diabetics and smokers Strongest mechanism—works systemically, not ju
This comparison does not assign a generated winner or score.
- Angiogenesis (VEGF upregulation)
- 340% increase in capillary density (rat models, 7 days post-injury)
- Improved wound perfusion measurable via laser Doppler
- NO pathway must be intact—blunted in diabetics and smokers
- Strongest mechanism—works systemically, not just at injection site
- Collagen I/III ratio modulation
- 40% reduction in keloid markers (hydroxyproline) at day 7; 25% higher tensile strength at day 14
- Reduced hypertrophic scarring in surgical wounds
- Timing critical—must start within 48 hours of injury
- Core anti-scarring effect—separates BPC-157 from generic wound accelerators
- Fibroblast migration
- 60% faster scratch assay closure in vitro
- Faster wound closure in superficial injuries
- Limited effect on deep tissue injuries without adequate vascular supply
- Meaningful for surface wounds; less impact on tendon/ligament injuries
- Dosing window
- Maximal effect when started <48 hours post-injury
- Diminishing returns after proliferative phase begins (day 4–7)
- Late initiation (>10 days post-injury) shows minimal benefit
- Start immediately post-injury—delayed protocols waste the peptide